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Abstract
Although numerous quantitative trait loci (QTL) influencing disease-related phenotypes have been detected through gene
mapping and positional cloning, identification of the individual gene(s) and molecular pathways leading to those
phenotypes is often elusive. One way to improve understanding of genetic architecture is to classify phenotypes in greater
depth by including transcriptional and metabolic profiling. In the current study, we have generated and analyzed mRNA
expression and metabolic profiles in liver samples obtained in an F2 intercross between the diabetes-resistant C57BL/6
leptin
ob/ob and the diabetes-susceptible BTBR leptin
ob/ob mouse strains. This cross, which segregates for genotype and
physiological traits, was previously used to identify several diabetes-related QTL. Our current investigation includes
microarray analysis of over 40,000 probe sets, plus quantitative mass spectrometry-based measurements of sixty-seven
intermediary metabolites in three different classes (amino acids, organic acids, and acyl-carnitines). We show that liver
metabolites map to distinct genetic regions, thereby indicating that tissue metabolites are heritable. We also demonstrate
that genomic analysis can be integrated with liver mRNA expression and metabolite profiling data to construct causal
networks for control of specific metabolic processes in liver. As a proof of principle of the practical significance of this
integrative approach, we illustrate the construction of a specific causal network that links gene expression and metabolic
changes in the context of glutamate metabolism, and demonstrate its validity by showing that genes in the network
respond to changes in glutamine and glutamate availability. Thus, the methods described here have the potential to reveal
regulatory networks that contribute to chronic, complex, and highly prevalent diseases and conditions such as obesity and
diabetes.
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Introduction
Geneticlinkageandassociationstudieshavethepowertoestablish
a causallink between genelociand physiologicaltraits.These studies
can make novel connections between biological processes that would
not otherwise be predictable based on current knowledge. The pace
of gene discovery has greatly accelerated in recent years, and
numerous quantitative trait loci (QTL) influencing disease-related
phenotypes have been identified through gene mapping and
positional cloning. While it has become relatively straightforward
to map a phenotype to a broad genomic region, identification of the
individual gene(s) responsible for the phenotype remains difficult.
Consequently, only a few percent of the many QTL that have been
mapped have had their underlying gene(s) identified [1–7]. Another
limitation of traditional QTL mapping is that it is based on
association with a physiological phenotype, but often does not reveal
the molecular pathways leading to that phenotype.
One way to uncover molecular mechanisms of disease states is
to broadly expand the types of phenotypes analyzed in genetic
screens. For example, with microarray technology, one can
measure the abundance of virtually all mRNAs in a segregating
sample. Importantly, mRNA abundance shows sufficient herita-
bility in outbred populations and experimental crosses to allow
mapping of gene loci that control gene expression, termed
expression QTL (eQTL) [8,9]. When eQTL co-localize with a
physiological QTL, one can hypothesize a shared regulator and
offer a potential pathway leading to the physiological trait [9,10].
The pathway between a QTL and a physiological trait often
involves changes in the steady-state levels of metabolic interme-
diates, in addition to changes in mRNA abundance. These
metabolites can correlate with the genetic, transcriptional,
translational, post-translational, and environmental influences on
phenotype [7,11]. Moreover, metabolites are intermediates in
signaling pathways that can regulate gene expression. For
PLoS Genetics | www.plosgenetics.org 1 2008 | Volume 4 | Issue 3 | e1000034example, fatty acids act as ligands for several of the PPAR nuclear
hormone receptors, bile acids activate FXR in liver, and
diacylglycerol regulates protein kinase C [12–14]. Metabolite
abundance reflects a biological response to exogenous and
endogenous inputs, and when investigating pathways from
genotype to phenotype, metabolites can provide a powerful
complement to gene expression data and give novel insights into
disease pathogenesis mechanisms [7,11,15–25].
Our laboratories have begun to apply targeted metabolic
profiling to study mechanisms underlying obesity-induced diabetes
[15–20], but have not yet attempted to integrate these methods
with genotyping and transcriptional profiling. This has included
the application of gas chromatography/mass spectrometry (GC/
MS) and tandem mass spectrometry (MS/MS) for measurements
of acyl-carnitine, organic acid, amino acid, free fatty acid, and
long and medium-chain acyl-CoA metabolites in tissue extracts
and bodily fluids. Herein, we have applied these methods to
measure various metabolites in liver samples from mouse strains
that differ in susceptibility to obesity-induced diabetes.
C57BL/6 (B6) leptin
ob/ob mice are obese but essentially resistant
to diabetes, whereas BTBR leptin
ob/ob mice are severely diabetic
[22]. In an F2 cohort derived from these parental strains, we have
shown that the range of blood glucose, insulin levels, and body
weight exceeds that of either the C57BL/6 (B6) leptin
ob/ob or BTBR
leptin
ob/ob parental strains. We went on to identify several diabetes-
related QTL in this F2 sample [21,22]. In the current study, we
focused on a subset of 60 F2 mice that have previously been
evaluated in detail with regard to liver gene expression profiles
[24] to ask if the abundances of hepatic metabolic intermediates
would show sufficient heritability to enable us to map metabolic
QTL (mQTL). Because we previously performed mRNA
expression profiling on liver samples from this F2 sample, we
were also able to investigate the potential for integrative analysis of
the expression profiling and metabolite data sets.
We show that liver metabolites do map to distinct genetic
regions, thereby demonstrating that tissue metabolite profiles are
heritable. In addition, we show that mQTL co-localize with
eQTL, suggesting common genetic regulators. Finally, as a proof
of principle of the practical significance of this multi-disciplinary
approach, we illustrate the construction of a specific causal
network that links gene expression and metabolic changes, and
demonstrate its validity by targeted gene expression analysis.
Results
Metabolites of Similar Function Are Highly Correlated
across the F2 Population
We determined the concentration of 67 liver metabolites,
comprised of 15 amino acids and urea cycle intermediates, 45
acyl-carnitines, and 7 organic acids (TCA cycle intermediates and
related metabolites) in the F2 sample. The specific analytes are
summarized in Table S1.
We created a correlation matrix of all pairwise comparisons
among individual metabolites. Unsupervised hierarchical cluster-
ing revealed several ‘‘hot spots’’ of highly correlated metabolites
(Figure 1). It is striking that several hot spots correspond to the
biochemical pathway to which the metabolites belong. For
example, 12 of the 15 amino acids cluster in this matrix.
Moreover, when we consider pairwise correlations between all
amino acids, 75% had absolute correlation coefficients greater
than 0.5 (p,0.01) (Table S2). Permutation analysis of these
pairwise correlations confirm that the 15 amino acids correlate as
a functional group (p,0.001). Several specific acyl-carnitine
derivatives are also clustered, such as hexadecadienoyl carnitine
(C16:2), 3-hydroxy-tetradecanoyl carnitine or dodecenedioyl
carnitine (C14:1-OH/C12:1-DC), and 3-hydroxy-palmitoleoyl
carnitine or cis-5-tetradecenedioyl carnitine (C16:1-OH/C14:1-
DC). The fact that metabolites of a common functional group are
highly correlated suggests that there are potential regulators of
these biochemical pathways segregating in this F2 sample.
In another cluster, pyruvate correlates most highly with alanine
(r=0.53, p,0.01), and also with lactate and tiglyl carnitine (C5:1)
(p,0.01). Alanine and short-chain acyl-carnitines are products of
peripheral protein and fatty acid catabolism, respectively, and are
delivered to the liver. The liver uses alanine, along with pyruvate
and lactate, as gluconeogenic substrates and rapidly interconverts
these metabolites through transamination and oxidation/reduc-
tion. The clustering of these metabolites based on their relative
concentration in F2 animals suggests that static metabolic profiling
can be used as a marker for changes in flux through certain
metabolic pathways. All metabolite-metabolite correlation coeffi-
cients are listed in Table S2.
It has been demonstrated that mRNA abundance, as deter-
mined with microarray technology, is sufficiently heritable to map
QTL [7,8,10,23–27]. Lan et. al. showed that using expression
mapping, specifically in this F2 intercross, can uncover mecha-
nisms that explain correlations between specific transcripts [8]. We
therefore sought to determine if metabolite abundance, as
measured in F2 liver samples by mass spectrometry, was similarly
heritable. If so, resulting metabolic QTL (mQTL) could be
integrated with expression QTL (eQTL) to form network models
of gene expression that might ultimately help to explain diabetes
susceptibility and resistance in the BTBR leptin
ob/ob and B6 leptin
ob/ob
strains, respectively [28,29].
We found that individual metabolites mapped to specific regions
of the genome. By permutation analysis, 21% of the metabolites
map significantly to genomic regions (LOD.5.0, p,0.05),
indicating those genomic regions could potentially influence
(either directly or indirectly) the abundance of these metabolites.
We used LOD threshold of 3.0 to investigate both major and
minor putative mQTL where groups of metabolites map. Figure 2
displays a heat map, with metabolites organized by hierarchical
Author Summary
Although numerous quantitative trait loci (QTL) influenc-
ing disease-related phenotypes have been detected
through gene mapping and positional cloning, identifying
individual genes and their potential roles in molecular
pathways leading to disease remains a challenge. In this
study, we include transcriptional and metabolic profiling in
genomic analyses to address this limitation. We investi-
gated an F2 intercross between the diabetes-resistant
C57BL/6 leptin
ob/ob and the diabetes-susceptible BTBR
leptin
ob/ob mouse strains that segregates for genotype
and diabetes-related physiological traits; blood glucose,
plasma insulin and body weight. Our study shows that
liver metabolites (comprised of amino acids, organic acids,
and acyl-carnitines) map to distinct genetic regions,
thereby indicating that tissue metabolites are heritable.
We also demonstrate that genomic analysis can be
integrated with liver mRNA expression and metabolite
profiling data to construct causal, testable networks for
control of specific metabolic processes in liver. We apply
an in vitro study to confirm the validity of this integrative
method, and thus provide a novel approach to reveal
regulatory networks that contribute to chronic, complex,
and highly prevalent diseases and conditions such as
obesity and diabetes.
Metabolic Networks Integrating mQTL and eQTL
PLoS Genetics | www.plosgenetics.org 2 2008 | Volume 4 | Issue 3 | e1000034C
2
2
C
2
0
C
1
0
:
2
C
i
t
r
a
t
e
C
1
0
:
3
T
y
r
C
3
C
1
0
:
1
C
2
0
:
1
-
O
H
/
C
1
8
:
1
-
D
C
C
8
:
1
C
i
4
-
D
C
/
C
4
-
D
C
C
1
2
-
O
H
/
C
1
0
-
D
C
C
1
0
-
O
H
/
C
8
-
D
C
C
1
4
-
O
H
/
C
1
2
-
D
C
C
1
8
:
1
-
O
H
/
C
1
6
:
1
-
D
C
C
1
6
-
O
H
/
C
1
4
-
D
C
C
1
4
:
1
C
2
C
1
6
:
2
C
1
4
:
1
-
O
H
/
C
1
2
:
1
-
D
C
C
1
6
:
1
-
O
H
/
C
1
4
:
1
-
D
C
L
a
c
t
a
t
e
P
y
r
u
v
a
t
e
C
1
2
:
1
C
5
:
1
A
l
a
C
2
0
-
O
H
/
C
1
8
-
D
C
C
2
0
:
4
C
1
8
:
1
C
1
6
:
1
M
a
l
a
t
e
F
u
m
a
r
a
t
e
S
u
c
c
i
n
a
t
e
g
l
u
t
a
r
a
t
e
G
l
x
H
i
s
A
r
g
A
s
x
O
r
n
P
r
o
G
l
y
V
a
l
L
e
u
/
I
l
e
S
e
r
M
e
t
P
h
e
C
5
-
O
H
/
C
3
-
D
C
C
6
C
4
/
C
i
4
C
5
s
C
1
8
-
O
H
/
C
1
6
-
D
C
C
1
8
C
1
8
:
2
-
O
H
C
1
8
:
2
C
1
6
C
4
-
O
H
C
6
-
D
C
C
8
:
1
-
D
C
C
1
4
:
2
C
1
2
C
i
t
C
1
4
C
7
-
D
C
C
1
0
C
6
:
1
-
D
C
/
C
8
:
1
-
O
H
C
8
C
5
-
D
C
C22
C20
C10:2
Citrate
C10:3
Tyr
C3
C10:1
C20:1-OH/C18:1-DC
C8:1
Ci4-DC/C4-DC
C12-OH/C10-DC
C10-OH/C8-DC
C14-OH/C12-DC
C18:1-OH/C16:1-DC
C16-OH/C14-DC
C14:1
C2
C16:2
C14:1-OH/C12:1-DC
C16:1-OH/C14:1-DC
Lactate
Pyruvate
C12:1
C5:1
Ala
C20-OH/C18-DC
C20:4
C18:1
C16:1
Malate
Fumarate
Succinate
glutarate
Glx
His
Arg
Asx
Orn
Pro
Gly
Val
Leu/Ile
Ser
Met
Phe
C5-OH/C3-DC
C6
C4/Ci4
C5s
C18-OH/C16-DC
C18
C18:2-OH
C18:2
C16
C4-OH
C6-DC
C8:1-DC
C14:2
C12
Cit
C14
C7-DC
C10
C6:1-DC/C8:1-OH
C8
C5-DC
Spearman’s 
Correlation
Coefficient
-0.5   0    0.5     1
Figure 1. Heat map of correlations between liver metabolites. Each square represents the Spearman’s correlation coefficient between the
metabolite of the column with that of the row (|r|.0.254, p,0.05; |r|.0.330, p,0.01). Metabolite order is determined as in hierarchical clustering using the
distance function 1-correlation. Self-self correlations are identified in black. Acyl-carnitines are annotated according to clinical acyl-carnitine profile shorthand
and amino acids by three letter code; other metabolite abbreviations are found in Table S1. Individual correlation coefficients can be found in Table S2.
doi:10.1371/journal.pgen.1000034.g001
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based on correlation (citrulline, tyrosine, and alanine are the
exceptions) map to common mQTL, e.g., an overlapping region of
chromosome 9. Amino acids that act together in specific pathways
show additional common mQTL. For example glx (glutamine+-
glutamate) and urea cycle intermediates arginine, asx (asparagi-
ne+aspartate), and ornithine, map to a common region of
chromosome 7. The gluconeogenic substrates alanine and
pyruvate have a mapping profile distinct from the majority of
amino acids in that they lack the prominent mQTL on
chromosome 9 (Figure 2). This unique alanine/pyruvate mQTL
may explain why alanine clusters with pyruvate rather than the
amino acids in the correlation matrix (Figure 1).
Expected and Novel Correlations between Transcripts
and Metabolites
The foregoing results demonstrate that metabolites of a
functional class often are correlated with one another and have
common mQTL. To better understand how gene expression and
metabolites are related, we adopted the approach used by Carrari
[30] and created a correlation matrix between liver metabolites
and selected liver transcripts of our 60 F2 mice. Three categories
of transcripts were chosen, based on gene ontology terms relating
to the biological process in which they play a role: 1) carbohydrate
metabolism (glucose metabolism, gluconeogenesis, glycolysis,
carbohydrate biosynthesis, TCA cycle, glucose transport, and
glycogen metabolism); 2) lipid metabolism (fatty acid biosynthesis,
fatty acid oxidation, steroid metabolism, cholesterol metabolism
and biosynthesis, and lipid biosynthesis); and 3) protein metabo-
lism (urea cycle, amino acid biosynthesis, protein catabolism, and
amino acid transport). We organized the metabolites into
functional classes to reveal whether biochemical groups of
metabolites correlated in a specific pattern with transcripts of a
particular pathway (Figure 3).
We found evidence for correlations among functionally similar
metabolites and transcripts when organized by biological process.
For example, several long-chain acyl-carnitine species show a
positive correlation with groups of transcripts involved in
glycolysis, fatty acid biosynthesis, steroid metabolism, cholesterol
metabolism, and lipid biosynthesis. In contrast, a subset of
medium-chain acyl-carnitines and short chain acyl-carnitines
exhibit a negative correlation to these same individual transcripts.
These findings are consistent with recent studies from our
laboratories showing that long-chain acyl-carnitines accumulate
in muscle of animals with diet-induced obesity at the expense of
short-chain acyl-carnitines, and that this abnormality is resolved
when obese animals are exercised [17].
The 15 amino acids displayed a common correlation pattern
with mRNA transcripts in pathways of protein metabolism, as
well as glycolysis, the TCA cycle, and several lipid metabolism
transcripts. These amino acids are very tightly correlated with
one another, leading us to investigate the role played by
individual transcripts in control of amino acid abundance. Our
data show that two very highly correlated metabolites often
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Figure 2. Linkage hot spots for metabolic quantitative trait loci (mQTL). Each row represents a marker; each column represents a
metabolite. Metabolites are ordered as in hierarchical clustering using the distance function 1-correlation (as in Figure 1). The LOD color scale is
indicated, showing blue (red) when the B6 (BTBR) allele at that marker results in an elevated level of metabolite.
doi:10.1371/journal.pgen.1000034.g002
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PLoS Genetics | www.plosgenetics.org 4 2008 | Volume 4 | Issue 3 | e1000034correlate with the same set of individual transcripts. However, we
also see that within this metabolite group, subsets of amino acids
will have a unique transcript correlation pattern (Table S3, Table
S4). For example, thirteen of fifteen amino acids correlate
(r.0.35, p,0.01) with Slc38a3, a sodium-dependent transporter
that mediates entry of a select group of amino acids across the
plasma membrane. There are pathways by which the few known
Slc38a3 amino acid substrates (alanine, asparagine, histidine, and
glutamine) could serve as precursors for biosynthesis of non-
substrate amino acids that also correlate with this transporter
[31,32]. In contrast, only valine and leucine+isoleucine correlate
as highly (r.0.35, p,0.01) with Ppargc1a mRNA, and could
represent a unique metabolic pathway involving the branched-
chain amino acids.
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Metabolites Produce Causal Network Models
One hypothesis that follows from our results is that unique
genetic regulators could affect the abundance of clusters of
metabolites. Unlike mRNA transcripts, metabolites can be
interconverted with other metabolites, generating a cluster to
which the precursor metabolite will be highly correlated [33]. The
downstream product metabolites will also be correlated with the
regulatory transcript and co-map with the eQTL of the regulatory
transcript [7,34].
Glutamate is a substrate and product in amino acid catabolic
and biosynthetic pathways. Glutamate can act either as an
ammonium donor or acceptor in transamination reactions (via a-
ketoglutarate) and the glutamate dehydrogenase reaction, and can
also be rapidly synthesized from glutamine via glutaminase, thus
providing precursor metabolites for the generation of other
organic acids and amino acids. Glutamine can also act as a
signaling molecule to alter expression of urea cycle and
gluconeogenic enzymes [35–39]. Given that glutamine and
glutamate (glx) can generate a network of related metabolites
and can also change gene expression, we focused on glx as the
start-point for building a proof-of-principle causal network from
the F2 liver expression and metabolite profiling data sets. We
generated a network featuring glx and a limited number of
transcripts that passed multiple, stringent selection filters (see
materials and methods). This provided a testable network that
would enable us to gain insights into metabolite-transcript
relationships.
Transcript nodes of the network are highly correlated to glx
(p,0.05 by 10,000 permutations) as well as other amino acids
(Table 1, Table S4). Table 1 depicts the overlap of the glx mQTL
interval and the physical location of the transcripts or their eQTL
encompassing a 1.5 LOD support interval around LOD peaks that
are at least 3.0 [40,41]. We note that glx is correlated with mRNA
of two transporters: sodium-dependent amino acid transporter
Slc38a3 and glutamate transporter Slc1a2, whose genes are located
on chromosomes 9 (102.5 Mb) and 2 (107.5 Mb), respectively.
Additionally, the glx mQTL on chromosome 9 spans a region
containing Slc38a3 and the mQTL on chromosome 2 and 9
overlaps with the eQTL of Slc1a2 (Table 1). We hypothesize that
both Slc1a2 and Slc38a3 could mediate the entry of glx into liver
cells, but that Slc1a2 may also have expression regulated by glx
abundance.
Table 1 also shows that glx is significantly correlated to
argininosuccinate synthetase 1 (Ass1), arginase 1 (Arg1), phospho-
enolpyruvate carboxykinase 1 (Pck1), isovaleryl coenzyme A
dehydrogenase (Ivd) and alanine:glyoxylate aminotransferase (Agxt)
mRNAs. The physical location and/or mapping location of these
transcripts with respect to the glx mQTL indicates that the
metabolite-transcript relationship may go beyond correlation. For
example, on chromosome 2, we see that the glx mQTL co-maps
with the eQTL for Agxt, Arg1, Ass1, and Ivd [41]. This is consistent
with network models in which the QTL regulates glx, which then
regulates gene expression or conversely, the QTL regulates
mRNA abunance of the four transcripts, which then regulate glx
[9].
Using the method described by Chaibub et al. (in review), we
generated a causal network consisting of glx and these highly
correlated transcripts (FDR=0.014), incorporating mQTL and
eQTL to determine directionality between the nodes (Figure 4).
This network model predicts that modulation of glutamine and/or
glutamate levels should lead to a change in the expression of Agxt,
Arg1, and Pck1. To test this prediction, we isolated hepatocytes
from lean B6 and BTBR parental strains and measured changes in
gene expression as a result of addition of 10 mM glutamine to the
cultured cells. Glutamine exposure changed transcript abundance,
and no transcript-specific strain differences in glutamine effect on
gene expression were found (p=0.53) (Figure 5). Glutamine
significantly increased expression of Agxt, Arg1, Pck1, and Ass1 in
both strains (p,0.05 for both strains); the increases in Pck1 and
Ass1 confirm prior studies [36–39].
Given its role as a glutamate transporter, it is not surprising that
Slc1a2 is upstream of glx in the best proposed causal network
(BF=163) (Figure 4, solid lines). However, glutamine exposure in
vitro reduced Slc1a2 expression in isolated hepatocytes from either
mouse strain, supporting the second-best causal network solution
(Figure 4, dotted lines). Glutamine also reduced Ivd expression in
the B6 strain but showed no effect in the BTBR strain, despite Ivd
being upstream of glx in our best causal network. Our causal
network predicts Slc38a3 should be unchanged by glutamine
treatment. Our hepatocyte experiments confirm this prediction
(Figure 5). Argininosuccinate lyase (Asl), which is neither correlated
nor co-maps with glx, served as a negative control and indeed was
not altered by glutamine treatment.
Discussion
Genomics, transcriptomics, proteomics, and metabolomics have
delivered large arrays of data, allowing one to correlate
physiological states with patterns of gene expression, protein
levels, and metabolite abundance. A major challenge in the
analysis and interpretation of this data is delivering models of
causation from correlations [9,42]. Mouse models of diabetes
provide a unique method for exploring correlation structure since
metabolic dysregulation creates a window for simultaneous
application of multiple ‘‘omic’’ technologies.
We have previously shown that diabetes traits show strong
heritability in an F2 intercross between the diabetes-resistant
C57BL/6 leptin
ob/ob and the diabetes-susceptible BTBR leptin
ob/ob
mouse strains. We assume that the disease phenotype is brought
about by a complex pattern of gene expression changes in key
tissues [21,22]. However, we also recognize the complexity
inherent in discriminating the gene expression changes that cause
diabetes from those that occur as a consequence of the disease. For
example, many genes are known to be responsive to elevated
blood glucose levels [43]. Through correlation alone, it is difficult
to distinguish these ‘‘reactive’’ genes from ones that are ‘‘causal’’
for the disease.
We have taken advantage of the high heritability of mRNA
abundance phenotypes, and via microarray technology, have
mapped gene loci controlling gene expression at the genome-wide
level [8]. This establishes at least one node in a network simply
because genetic variation leads to changes in gene expression and
not vice versa. However, it does not establish whether the link
between a locus and a phenotype is direct or via multiple steps and
pathways [27,44].
The purpose of the current study was to explore the possibility
that the levels of metabolites in tissues are sufficiently heritable in
an F2 intercross to provide significant linkage signals, leading to
metabolic QTL. Given that many pathways converge upon
common metabolites and that these pathways have multiple
controllers, any one genetic locus may not alter metabolite levels
significantly, and therefore may not be identified as a metabolite
QTL. Nonetheless, in our F2 sample, we found significant linkage
signals, including some that are quite strong (e.g. tyrosine:
LOD.7, p,0.005; chromosome 2).
Our results reveal that metabolites can be mapped to distinct
genetic regions, much like mRNA transcripts. Although QTL
Metabolic Networks Integrating mQTL and eQTL
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identify individual genes with high certainty, it can yield novel
information about regulatory networks. Phenotypes mapping to
the same locus can be hypothesized to be co-regulated by that
locus. With our definition of ‘‘phenotype’’ now including
transcripts, metabolites, and physiological traits, we can begin to
devise relationships between these phenotypes and genetic regions.
This F2 study provides evidence of co-regulation of biologically
related pathways. An example is the correlations we found
between amino acids and short-chain acyl-carnitine derivatives.
These findings are consistent with our understanding of metabolic
physiology. In a catabolic, ‘‘glucose starved’’ state, muscle
degrades proteins and delivers amino acids to the liver for glucose
production. The liver transaminates amino acids to corresponding
a-keto acid gluconeogenic substrates. Alpha-ketoglutarate is often
the a-keto acid acceptor for these transaminase reactions,
generating glutamate as a product. Glutamate, which can also
be generated from glutamine in the glutaminase reaction, is then
deaminated to produce ammonia by glutamate dehydrogenase, to
be fixed through the urea cycle. Additionally, hepatic fatty acid
oxidation and amino acid catabolism yield even and odd-
numbered short-chain acyl CoAs, which can be used for fuel
and for production of ketone bodies. These short-chain acyl-CoA
species are readily converted to the cognate carnitine esters, which
we have profiled by MS/MS in this study.
The amino acid metabolites provide the most striking evidence
of functional clustering. We see in both the correlation matrix
(Figure 1) and the genetic linkage data (Figure 2) that the majority
of amino acids group together. However, a subset of the amino
acids, asx, glx, arginine, and ornithine uniquely map to
chromosome 7. Our data predict that these metabolites are driven
by different genetic regulators, leading to a unique mapping
signature, even within a group of highly correlated metabolites.
The C/EBP transcription factors have been shown to alter
expression of enzymes acting in the urea cycle and gluconeogenic
pathway [45–51], and the C/EBPa isoform is encoded on
chromosome 7. Although we cannot determine that metabolites
are mapping to the same individual genes, we can identify genetic
regions that coordinate groups of metabolites and transcripts and
contain plausible candidate genes.
The relationship between mRNA transcripts and metabolites,
however, can be bi-directional. Our network identifies a specific
metabolite, glx that regulates gene expression. This is consistent
with previous studies where glutamine alone increases hepatic
expression of argininosuccinate synthetase and phosphoenolpyr-
uvate carboxykinase, but when combined with other essential
amino acids, alters additional transcripts of urea cycle and
gluconeogenic pathways [36–38,52]. Our work extends these
prior observations by showing that glutamine also changes
expression of Agxt, Arg1, Ivd, and Slc1a2, but does not alter
Slc38a3, despite the positive correlation with this transcript. The
combination of pathway construction based on transcriptional and
metabolic profiling and direct model testing in living cells provides
evidence for a new pathway by which glx can regulate a key
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Figure 4. Glx network. This network consists of a select number of transcripts (grey circles) among the 250 mRNA that are most correlated to glx
(black rectangle) (p,0.002). The microsatellite marker (Mb) for peak eQTL or mQTL altering levels of transcripts and metabolites, respectively, are
given. For any two phenotypes connected by an edge, the direction LOD score and p-value are indicated (insert). The best solution was determined
by an approximate Bayes factor (BF) and indicated in solid lines, the second best solution in dotted lines.
doi:10.1371/journal.pgen.1000034.g004
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if this pathway is perturbed in development of diabetes.
The glutamine induced reduction in Slc1a2 expression was
unexpected given that this glutamate transporter is upstream of glx
in the best-proposed causal network (Figure 4, solid lines). Slc1a2
mRNA abundance, however, maps in trans (to a locus distinct from
the physical location of the gene) to chromosome 9, its eQTL
overlapping with the glx mQTL. It is therefore possible that
glutamine could regulate Slc1a2, as indicated by the second causal
network (Figure 4, dotted lines). Several studies have shown that
Slc1a2 expression in astrocytes is reduced by increased ammonia
[45–47,51,53–55]. Despite the positive correlation between Slc1a2
and glx in vivo, the glutamine-treated hepatocytes produce
ammonia via glutaminase, and could decrease expression of
hepatic Slc1a2 in vitro. We also did not predict altered expression
of Ivd, an enzyme of leucine oxidation. It is interesting to note that
Ivd is a case where a gene maps both in cis (to the locus containing
the Ivd gene) and in trans, here overlapping with the glx mQTL on
chromosomes 2 and 13. Studies have shown that glutamine has an
inverse relationship with leucine oxidation, and this could be
mediated by glutamine-induced decreased Ivd expression [48,50].
We show that the combined use of eQTL and mQTL, with
correlations allows one to derive a network and establish data-
driven hypotheses about metabolite and gene expression relation-
ships. For example, glycine and serine are the two amino acids
most highly correlated with glx, and the transcript most highly
correlated with glx is Agxt (Table 1, Table S2). Indeed, in our
experiments, Agxt was upregulated by glutamine. We hypothesize
that the upregulation by glx of Agxt is one mechanism by which glx
is correlated with glycine and serine since Agxt catalyzes the
transamination of glyoxalate to form glycine, which can then be
converted to serine. In further support of this hypothesis, in the F2
sample, serine and glycine correlate (r.0.5, p,0.01) to Agxt.
The concurrent use of transcriptomics and metabolomics is not
limited to one biochemical pathway. For example, the correlation
between amino acids and transcripts of carbohydrate and lipid
metabolism might reflect a broader signaling function of amino
acids beyond pathways of protein metabolism. Furthermore, this
correlation, co-mapping, and causal network analysis can uncover
roles for transcripts of unknown function. We note Riken clones
and ESTs are among the transcripts highly correlated to individual
metabolites (Table S3). By incorporating these transcripts of
unknown function as nodes into causal networks, along with
transcripts from known pathways, we may infer the functions of
these previously unidentified mRNA species.
In conclusion, this study shows that metabolites, in addition to
transcripts and physiological traits, can be mapped to genetic
regions, providing a powerful tool to establish connections
between genetic loci and physiological traits. The groups of
metabolites and transcripts that are correlated or co-map to
physiological traits in our F2 sample may offer insight into
metabolic pathways that are causal or reactive to diabetes
pathology.
Materials and Methods
Animals
BTBR, B6, and B6-ob/+ mice were purchased from The
Jackson Laboratory (Bar Harbor, ME) and bred at the University
of Wisconsin. The lineage and characteristics of the BTBR strain
have been reviewed by Ranheim et al. Mice were housed in an
environmentally controlled facility (12-hour light and dark cycles)
and were weaned at 3 weeks of age onto a 6% fat diet (Purina;
#5008). Mice had ad libitum access to food and water, except for
4 hour fasting periods before blood draws and killing (by CO2
asphyxiation). Plasma glucose levels were measured using a
commercially available kit (994-90902; Wako Chemicals). Plasma
insulin levels were measured by radioimmunoassay (RI-13K;
Linco Research).
The facilities and research protocols were approved by the
University of Wisconsin Institutional Animal Care and Use
Committee.
Genotyping
Sixty F2 leptin
ob/ob mice ranging in age from 13 to 26 weeks were
genotyped as previously described [22]. Mapmaker/EXP was used
to compile genotype data into framework map.
RNA Collection and Microarray
Liver RNA was arrayed as described in Lan et. al [8]. Ten to
12 week old male and female F2 leptin
ob/ob mice were killed by CO2
asphyxiation after a 4-h fast. Total RNA from sixty F2 mice using
RNAzol reagent (Tel-Test) and was further purified using an
RNeasy kit (Qiagen). The sample labeling, microarray hybridiza-
tion, washing, and scanning were performed according to the
manufacturer’s protocols (Affymetrix). Labeled cRNA was pre-
pared and hybridization assay procedures including preparation of
solutions were carried out as described in the Affymetrix
GeneChip Expression Analysis Technical Manual. A total of 60
MOE430A and MOE430B arrays were used to monitor the
expression levels of approximately 45,000 genes or ESTs. The
distribution of fluorescent material on the array was obtained
using G2500A GeneArray Scanner (Affymetrix). Microarray Suite
(MAS) version 5.0 and GeneChip Operating Software (GCOS)
supplied by Affymetrix was used to perform gene expression
analysis. Expression levels of all the transcripts were estimated
using the RMA algorithm [49].
BTBR
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Figure 5. Glutamine changes hepatic gene expression. Hepato-
cytes from 10-week old lean B6 (A) and BTBR (B) were treated overnight
+/2 10 mM glutamine (n=5 per strain). Transcripts were measured by
RT-PCR and expression was normalized to Actb control. Significance
calculated based on the difference of delta CT value of each transcript
between the untreated and glutamine treated hepatocytes for each
individual animal (*p,0.05, **p,0.005).
doi:10.1371/journal.pgen.1000034.g005
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Amino acids, acyl-carnitines and organic acids were measured
using stable isotope dilution techniques [15,18,56]. Amino acids
and acyl-carnitine species were measured using flow injection
tandem mass spectrometry and sample preparation methods
described previously [15,56]. Briefly, samples were equilibrated
with a cocktail of internal standards, de-proteinated by precipita-
tion with methanol, aliquoted supernatants were dried, and then
esterified with hot, acidic methanol (acyl-carnitines) or n-butanol
(amino acids). The data were acquired using a Micromass Quattro
micro TM system equipped with a model 2777 autosampler, a
model 1525 m HPLC solvent delivery system and a data system
controlled by MassLynx 4.0 operating system (Waters, Milford,
MA) [15,56]. Organic acids were quantified using a previously
described method that utilizes Trace GC Ultra coupled to a Trace
DSQ MS operating under Excalibur 1.4 (Thermo Fisher
Scientific, Austin, TX) [18].
Sixty-seven liver metabolites were measured, comprised of 15
amino acids and urea cycle intermediates, 45 acyl-carnitine
derivatives, and 7 organic acids (TCA cycle intermediates and
related analytes). The specific metabolites are listed in Table S1.
All MS analyses employed stable-isotope-dilution. The standards
serve both to help identify each of the analyte peaks and provide
the reference for quantifying their levels. Quantification was
facilitated by addition of mixtures of known quantities of stable-
isotope internal standards from Isotec (St. Louis, MO), Cambridge
Isotope Laboratories (Andover, MA), and CDN Isotopes (Pointe-
Claire, Quebec, CN) to samples, as follows: Acyl-carnitine assays–
D3-acetyl, D3-propionyl, D3-butyryl, D9-isovaleryl, D3-octanoyl,
and D3-palmitoyl carnitines; Amino acid assays–
15N1,
13C1-gly-
cine, D4-alanine, D8-valine, D7-proline, D3-serine, D3-leucine, D3-
methionine, D5-phenylalanine, D4-tyrosine, D3-aspartate, D3-
glutamate, D2-ornithine, D2-citrulline, and D5-arginine; Organic
acid assays–D3-lactate, D3-pyruvate,
13C4-succinate, D2-fumarate,
D4-glutarate,
13C1-malate, D6-alpha-ketoglutarate, and D3-citrate.
In addition to mass, analytes are identified on the basis of the
particular MS/MS transitions that we monitor for each class of
metabolites. For example, all acyl-carnitine methyl esters produce
a fragment m/z 99. We make the assumption that all even mass
precursors ions of m/z 99 are acyl-carnitines to which we assign
plausible molecular structures. We differentiate isobaric structures
e.g., dicarboxylic and hydroxylated acyl-carnitines, by comparing
of MS/MS spectra for precursors of m/z 85 butylated acyl-
carnitine species. We can infer whether the original compound
had one or two carboxyl groups on the basis of the mass change
from methyl to butyl esters.
Given our sample size, we initially analyzed metabolite
abundance by hierarchical clustering using the distance function
1-correlation [40,57–60]. Pairwise Spearman correlation coeffi-
cients of r.0.254 and r.0.330 reflected p-values p,0.05 and
p,0.01, respectively. To test whether the 15 amino acids are
significantly correlated as a group, groups of 15 metabolites were
permuted 1,000 times and the percentage of pairwise correlations
exceeding 0.5 was recorded for each group. The fifteen amino
acids cluster significantly as a group based on 1,000 permutations
(p,0.001).
QTL Analysis
Detection and mapping of QTL was performed as previously
described [8,22]. Briefly, genotypes of 512 F2 mice at 293 markers
were assembled using MAPMAKER/EXP [61]. A previously
established subset of 60 mice with transcript data was used for
expression QTL analysis [24]. Interval mapping methods adjusted
for sex as implemented in R/qtl [62] were used to compute linkage
to the traits of interest and to investigate mode of inheritance. The
traits included the 45,265 probe sets surveyed by microarray
analysis, and the 67 liver metabolites assayed by MS methods.
We used standard interval mapping implemented in R/qtl to
map each of the transcripts and liver metabolites at 1-cM
resolution with age as additive covariates and sex as both additive
and interactive covariates [62]. A LOD threshold of 5.0 is required
to reach a level of p,0.05 in this data set with sample size 60
based on 10,000 permutations. We used threshold of 3.0 in order
to highlight genetic regions to which groups of metabolites map.
To visualize regions of mQTL co-localization in highly correlated
metabolites (Figure 2), we constructed heat maps where metab-
olites are ordered as in hierarchical clustering using 1-correlation,
as in Figure 1. When mice with the B6 allele at a marker have
greater levels of metabolites on average than mice with the BTBR
allele at that marker, the LOD score at that marker is multiplied
by 21. This adjustment allows us to visualize whether the B6 or
BTBR allele results in elevated metabolite abundance.
In Vitro Hepatocyte Experiments
Hepatocytes from 10-week lean male and female BTBR and B6
parental strain mice (n=5 for each genotype) were isolated by liver
perfusion [63]. Hepatocytes were seeded at subconfluency (3.5 6
10
6 cells/6 well plate) in low glucose DMEM (GIBCO) supple-
mented with FBS (10% vol/vol; GIBCO), pen/strep antibiotic
(1%, GIBCO), glutamine (2 mM; GIBCO), and pyruvate (1 mM;
GIBCO). Cells were left to attach for 3 hours in an incubator at
37uC, 5% CO2. After a wash with PBS, the cells were treated with
unsupplemented DMEM (Sigma) with 1 g/L glucose, pen/strep
(1%), and +/2 10 mM glutamine. Cells were treated for 24 hours.
RNA was extracted from hepatocytes using RNeasy kits
(Qiagen) after treatment described above. Hepatocytes in 6-well
plates were homogenized in 0.35 ml of RLT buffer and stored at
280 C. RNA was purified using RNeasy-mini columns (Qiagen)
according to the manufacturer’s directions. The ratio of the optical
densities from RNA samples measured at 260 and 280 nm was
used to evaluate nucleic acid purity and total RNA concentrations
were determined by the absorbance at 260 nm. The quality of
total RNA was estimated based on the integrity of 28S and 18S
rRNA separated using 1% agarose gel electrophoresis.
Gene expression was measured using a 7500 fast real-time PCR
system (Applied Biosystems). cDNA was synthesized from 1 ug of
total RNA using the SuperScriptIII first-strand cDNA synthesis kit
(Invitrogen) primed with a mixture of oligo-dT and random
hexamers. Primers were obtained from Integrated DNA Tech-
nologies and MWG Biotechnology. The SYBR Green PCR core
reagent kit (Applied Biosystems) was used to determine relative
expression. The housekeeping gene Actb was used as a normali-
zation control. Primer sequences and gene accession codes for
transcripts of the glx network are provided in Table S5.
Networks
Causal networks were constructed using the methods of
Chaibub, et al. (in review). Although the network has the ability
to accommodate 100 or more transcripts, we chose a limited
number of transcripts passing several selection filters. The
transcripts for the glx network were derived from the top 250
most correlated transcripts (p,0.002) according to the WebQTL
software (www.genenetwork.org). A hypergeometric test was
performed and identified the GO term category ‘‘metabolism’’
as one of the two processes significantly enriched by these
correlates (p,0.004). Transcripts were chosen from this category,
with an additional requirement being that they have at least one
eQTL overlapping with the glx mQTL (Table 1). QTL in the
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LOD peaks that are at least 3.0 are also included [41,42]. Based
on 10,000 permutations for each of the transcripts, the LOD
threshold is significantly higher to reach significance (LOD.5.0 is
required for p,0.05), but the 3.0 threshold was used include
major and minor putative QTL [8,24].
If more than one probe set was used to identify a transcript of
interest, only probe sets with a grade A annotation on Affymetrix
were considered. For these probe sets, only those with all eleven
oligonucleotides aligning (via BLAST) to their appropriate target
sequence provided by the National Center for Biotechnology
Information (www.ncbi.nlm.nih.gov) were considered acceptable.
If more than one primer set still identified the transcript, an
average of the probe sets in the network.
We built an undirected dependency graph (UDG) of order 6
with glx and these transcripts as nodes with a two-tailed
significance level of 0.05 [64]. We remove edges that are based
on spurious or partial correlations, and then orient causal edges
between all pairs of connected phenotypes using associated
multiple QTLs to break likelihood equivalence. Quantitative trait
loci for glx and the selected transcripts were identified with R/qtl
[62] using a 3.0 LOD cutoff; the marker closest to each peak
provided key information for inferring causal direction. We
oriented phenotype edges using our QTL-directed dependency
graph (QDG) approach. For any two phenotypes connected by an
edge, the direction LOD score was computed by regressing these
phenotypes on each other and on their respective multiple QTLs,
adjusting for age and for QTL-sex interactions, and by other
phenotypes that might be directly connected to either phenotype
by an UDG edge. For each edge, we evaluate a LOD score
comparing the two possible orientations and we orient the edge in
favor of the direction with the higher likelihood in the ratio. P-
values for the direction of the edges were computed using 10,000
permutations. Our QDG algorithm used random starts to
converge to possible solutions. The best solution was determined
by an approximate Bayes factor (BF) [65,66]. A detailed materials
and methods section describing the construction of causal
networks is provided in Supporting Protocols (Protocol S1).
We estimated network parameters from the true data and
simulated synthetic data according to the causal network in
Figure 4. We simulated 1,000 realizations from the causal network
and for each edge, we recorded the percentage of undirected edges
recovered by the UDG algorithm and the percentage correctly
inferred direction by the orientation steps of the QDG algorithm.
Overall, the average percentage of true recovered edges was 75%
and the average percentage of correctly inferred direction was
83%. False edges were detected at a rate below 2%. To calculate
the false discovery rate for the network, we simulated 1,000 data
sets from the true network. For each data set, the UDG algorithm
was used to infer the network topology, and computed the fraction
of false edges (those detected that do not exist in the true network)
relative to the total number edges detected by the UDG algorithm.
The FDR for the network topology, computed as the average
fraction for these 1,000 simulations, is 0.014.
Gene Expression Analysis
The fold changes relative to the untreated hepatocytes for each
animal were calculated. An overall ANOVA analysis was
performed with gene transcripts nested within subject; interest
focused on gene transcript effects and possible gene transcript
differences between strains. This analysis showed that glutamine-
induced expression change differed by gene (p,0.0001). Signif-
icant overall gene transcript effects allows separate transcript-
specific paired t-tests between the difference in delta CT values of
untreated and glutamine induced gene expression (relative to Actb)
in each strain separately. Statistics on these data were analyzed
with Prism software version 4.02 (Graph Pad Software) and the
aov command in R (www.r-project.org).
Supporting Information
Protocol S1 Causal network reconstruction.
Found at: doi:10.1371/journal.pgen.1000034.s001 (0.05 MB
DOC)
Table S1 Metabolite codes. Acyl-carnitines are annotated
according to clinical acyl-carnitine profile shorthand; conventional
amino acids are annotated by their three-letter code. In the cases
where two acyl-carnitine derivatives were unable to be distin-
guished by MS analysis alone, both are reported, indicating that
either analyte could be the predominant species.
Found at: doi:10.1371/journal.pgen.1000034.s002 (0.02 MB
XLS)
Table S2 Metabolite correlation matrix. All pairwise correla-
tions between the 67 metabolites were calculated and recorded as
the Spearman’s correlation coefficient (|r|.0.254, p,0.05;
|r|.0.330, p,0.01). Metabolites are ordered according to the
strength of their correlation as in Figure 1.
Found at: doi:10.1371/journal.pgen.1000034.s003 (0.10 MB
XLS)
Table S3 Correlation of amino acids and individual transcripts
metabolic pathways. Transcripts that had Spearman’s correlation
r.0.4 to any individual amino acid are included (|r|.0.254,
p,0.05; |r|.0.330, p,0.01). The physical location of the gene is
provided (Mb). Amino acids are ordered as in Figure 3.
Found at: doi:10.1371/journal.pgen.1000034.s004 (0.81 MB
XLS)
Table S4 Glx network correlations. The Spearman’s correlation
coefficient of the 15 individual amino acids with the transcripts of
the glx network is recorded (|r|.0.254, p,0.05; |r|.0.330,
p,0.01). Amino acids are ordered as in Figure 3.
Found at: doi:10.1371/journal.pgen.1000034.s005 (0.02 MB
XLS)
Table S5 Primer sequences. Integrated DNA Technologies
(Agxt, Pck1, Slc38a3) and MWG Biotechnology (Actb, Arg1,
Asl, Ass1, Ivd, Slc1a2).
Found at: doi:10.1371/journal.pgen.1000034.s006 (0.02 MB
XLS)
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